USPTO Examiner HOLLOMAN NANNETTE - Art Unit 1612

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18775688COMPOSITION & METHODS FOR REGULATING MELANOGENESISJuly 2024October 2024Allow300NoNo
18761235STRUCTURALLY DIVERSE, STABLE, AND RADIATION-PROTECTIVE PARTICLE MATRIX SUNSCREEN AND COSMETIC COMPOSITIONS AND RELATED METHODSJuly 2024June 2025Allow1210NoNo
18444424SUNSCREEN FORMULATIONS AND METHODS OF MAKING AND USING THE SAMEFebruary 2024April 2025Allow1420YesNo
18438591EXTRUDABLE PHOTOCROSSLINKABLE HYDROGEL AND METHOD FOR ITS PREPARATIONFebruary 2024September 2024Allow700NoNo
184152072-(BENZO[B]THIOPHEN-3-YL)-1-BUTYL-4,5-DIPHENYL-1H-IMIDAZOLE AS AN ANTI-INFLAMMATORY AND ANTI-MICROBIAL COMPOUNDJanuary 2024April 2024Allow300NoNo
184151622-(BENZO[B]THIOPHEN-3-YL)-1-BUTYL-4,5-DIPHENYL-1H-IMIDAZOLE AS AN ANTI-INFLAMMATORY AND ANTI-MICROBIAL COMPOUNDJanuary 2024April 2024Allow300YesNo
18399796COSMETIC COMPOSITION DERIVED FROM NATURAL PRODUCTS FOR IMPROVING SKIN HEALTHDecember 2023January 2025Allow1310NoNo
18544975SPRAYABLE COMPOSITIONS CONTAINING OIL-IN-WATER EMULSIONS CONTAINING SUBMICRON HYDROPHOBIC AGENTS AND METHODS OF USE THEREOFDecember 2023March 2025Allow1510NoNo
18516303COMPOSITION FOR SUNSCREEN COSMETICSNovember 2023January 2025Abandon1410NoNo
18508746Oral Care Compositions and Methods of UseNovember 2023May 2025Allow1820NoNo
1838586112-BROMO-2,16-DIOXA-9,9,18,18-TETRAMETHYLPENTACYCLO[7.7.5.0 1, 21.0 3,8.0 10,15]HENICOSA3(8),10,12,14-TETRAENE-7,20-DIONE AS AN ANTIMICROBIAL COMPOUNDOctober 2023February 2024Allow410NoNo
18488030STRUCTURALLY DIVERSE, STABLE, AND RADIATION-PROTECTIVE PARTICLE MATRIX SUNSCREEN AND COSMETIC COMPOSITIONS AND RELATED METHODSOctober 2023March 2024Allow500NoNo
18485560LIPO-AMINO ACID ALKYL ESTERS AS SPF BOOSTERSOctober 2023January 2025Abandon1510NoNo
18484963METHODS AND COMPOSITIONS TO INCREASE HAIR GROWTH AND/OR PREVENT HAIR LOSSOctober 2023April 2025Allow1810NoNo
18474923DEVICE AND METHOD FOR PROVIDING CUSTOMIZED SKIN COLOR MATCHING SUNSCREENSeptember 2023April 2025Allow1810NoNo
182424652-(BENZO[B]THIOPHEN-3-YL)-1-BUTYL-4,5-DIPHENYL-1H-IMIDAZOLE AS AN ANTI-INFLAMMATORY AND ANTI-MICROBIAL COMPOUNDSeptember 2023April 2024Allow721NoNo
18366067Oral Care Compositions and MethodsAugust 2023April 2025Allow2020NoNo
18227489SUNSCREEN COMPOSITION COMPRISING VISIBLE LIGHT PROTECTING AGENTS AND METHODS OF USEJuly 2023June 2025Allow2310NoNo
18273684TOPICAL PHARMACEUTICAL COMPOSITION CONTAINING PHOSPHOLIPIDSJuly 2023August 2024Allow1311YesNo
18198369COMPOSITION OF CHLORHEXIDINEMay 2023February 2024Allow930YesNo
18307373THERAPEUTIC PUTTIES CONTAINING ADDITIVES INCLUDING PROCESSED HUMAN BLOOD PLASMAApril 2023January 2025Allow2110NoNo
18304685Compositions Containing IbrutinibApril 2023February 2025Abandon2130NoNo
18246804A PRODUCT FOR TREATING SKIN FUNGUS AND ITS MICRONIZED PREPARATION METHODMarch 2023August 2024Allow1721NoNo
18107060NOVEL HIGHLY SUSTAINABLE COMPOSITIONS FOR MODULATION OF GENE EXPRESSION IN HUMAN SKIN, AND METHODS OF PRODUCTION THEREOFFebruary 2023October 2024Allow2010NoNo
18151269FENOLDOPAM TOPICAL FORMULATIONS FOR TREATING SKIN DISORDERSJanuary 2023May 2025Abandon2810NoNo
18091492METHODS FOR CONTINUOUS MANUFACTURE OF LIPOSOMAL DRUG PRODUCTSDecember 2022December 2024Allow2410NoNo
18091556ORAL FILM COMPOSITIONS AND DOSAGE FORMS HAVING PRECISE ACTIVE DISSOLUTION PROFILESDecember 2022July 2023Allow720NoNo
18083840Personal Care CompositionsDecember 2022April 2025Allow2810NoNo
18059726LIPIDATED IMMUNE RESPONSE MODIFIER COMPOUND COMPOSITIONS, FORMULATIONS, AND METHODSNovember 2022September 2024Allow2110NoNo
18070572SKIN CARE COMPOSITIONNovember 2022June 2025Allow3100NoNo
17989307ORAL FILM COMPOSITIONS AND DOSAGE FORMS HAVING PRECISE ACTIVE DISSOLUTION PROFILESNovember 2022December 2024Allow2510NoNo
17925846A HIGH SPF SKIN CLEANSING COMPOSITIONNovember 2022September 2023Allow1010NoNo
18054816TESTOSTERONE TRANSDERMAL SPRAY WITH FILMNovember 2022September 2024Allow2210NoNo
17984761PHOSPHATIDYLCHOLINE LIPID LIPOSOMES AS BOUNDARY LUBRICANTS IN AQUEOUS MEDIANovember 2022March 2025Allow2810NoNo
17975892COSMETIC COMPOSITIONOctober 2022February 2024Allow1511NoNo
18045974COMPOSITION FOR PROMOTING HAIR GROWTHOctober 2022December 2023Allow1410NoNo
17962115METHODS FOR TREATING PULMONARY NON-TUBERCULOUS MYCOBACTERIAL INFECTIONSOctober 2022August 2024Allow2210NoNo
17917282LAMINARIN BASED FORMULATION FOR AGRICULTURAL APPLICATIONSOctober 2022June 2025Allow3310NoNo
17951726SKIN CARE MASK AND METHOD OF MANUFACTURESeptember 2022October 2023Allow1320NoNo
17951988INORGANIC SUNSCREEN ACTIVE AGENTS IN COSMETIC COMPOSITIONS AND METHODSSeptember 2022October 2023Abandon1210NoNo
17902741COMPOSITION FOR SUNSCREEN COSMETICSSeptember 2022January 2023Allow410NoNo
17895911SUNSCREEN COMPOSITION AND METHODS OF PROTECTION FROM ULTRAVIOLET AND VISIBLE LIGHTAugust 2022April 2024Allow2010NoNo
17820548PERSONAL CARE COMPOSITION CONTAINING SPHERICAL SILICONE ELASTOMER FINE PARTICLESAugust 2022September 2024Allow2500NoNo
17888587Malodor Suppression in Brassica Amidoalkyl Containing Cosmetic CompositionsAugust 2022May 2024Allow2120NoNo
17803532METHOD OF ENCOURAGING GROWTH AND REGROWTH OF HAIR IN HUMAN MALES TECHNICAL AREAAugust 2022June 2023Allow1000NoNo
17819350Binder For Use In Powdery Cosmetic CompositionsAugust 2022June 2023Allow1100NoNo
17881411MASKAugust 2022March 2024Abandon1920NoNo
17876837HYBRID MINERAL AND ORGANIC DAILY SUNSCREEN THICK CREAM MOISTURIZERJuly 2022January 2024Allow1710NoNo
17868419HAIR OILJuly 2022January 2024Allow1810NoNo
17813237SUNSCREEN COMPOSITION CONTAINING VISIBLY TRANSPARENT BIOCOMPATIBLE ULTRAVIOLET BLOCKING POLYMER NANOPARTICLESJuly 2022March 2024Allow2000NoNo
17812254ARTIFICIAL BETA CELLS AND METHODS OF USE THEREOFJuly 2022September 2024Allow2600NoNo
17811970PHARMACEUTICAL FORMULATIONJuly 2022December 2024Allow3010NoNo
17811817Hoof treatment comprising Chlorine DioxideJuly 2022December 2023Abandon1810NoNo
17860389TOPICAL COMPOSITIONS CONTAINING ROSE OIL AND CANNABIDIOL AND METHODS OF MAKING AND USING THE SAMEJuly 2022October 2024Allow2710NoNo
17853005METHODS AND COMPOSITIONS FOR TREATMENT OF PULMONARY HYPERTENSION AND OTHER LUNG DISORDERSJune 2022November 2024Allow2910NoNo
17850931Complexation of Curcumin with Calixarene DerivativesJune 2022June 2023Allow1211NoNo
17848608Natural 1,2-Alkanediols, Compositions Having Natural 1,2-Alkanediols and Processes for Making the SameJune 2022October 2024Abandon2810NoNo
17847455Bacterial Cellulose-Polyurethane Composite Material, Preparation Method Therefor, and Application ThereofJune 2022June 2025Allow3601NoNo
17788565WATER-IN-OIL EMULSION COSMETIC PREPARATION FOR SKINJune 2022June 2025Allow3610NoNo
17845688METHODS FOR TREATING PULMONARY NON-TUBERCULOUS MYCOBACTERIAL INFECTIONSJune 2022August 2024Allow2510NoNo
17844930COSMETIC COMPOSITION COMPRISING NATURAL EMULSIFIERS AND THIOPYRIDINONE COMPOUNDSJune 2022October 2024Allow2711NoNo
17838523COMPOSITION AND METHOD FOR A TOPICAL TREATMENT FOR VENOM NEUTRALIZATIONJune 2022September 2023Abandon1510NoNo
17784181COMPOSITION COMPRISING AT LEAST 5% BY WEIGHT OF TITANIUM OXIDES, AN a-CYANODIPHENYLACRYLATE DERIVATIVE AND A 4-HYDROXYBENZYLIDENEMALONATE OR 4-HYDROXYCINNAMATE DERIVATIVEJune 2022June 2025Allow3610NoNo
17831207Composition for a Skin and Hair ProductJune 2022January 2023Allow700NoNo
17826315ORGANIC SUNSCREEN COMPOSITION AND PROCESS FOR PROTECTING SKIN FROM PHOTODAMAGE AND AGINGMay 2022June 2025Allow3721NoNo
17662275MACADAMIA INTEGRIFOLIA WHITENING EXTRACT AND PREPARATION METHOD THEREOFMay 2022December 2022Allow800NoNo
17738713SHAMPOO COMPOSITIONMay 2022June 2023Allow1410NoNo
17730571Mitochondrial Performance Enhancement Nanoemulsion MethodApril 2022January 2025Allow3301NoNo
17660313TRANSDERMAL THERAPEUTIC SYSTEM CONTAINING ASENAPINE AND POLYSILOXANE OR POLYISOBUTYLENEApril 2022November 2024Allow3130NoNo
17723398TRANSDERMAL SOLVENT SYSTEM AND METHODS OF USEApril 2022March 2024Allow2310NoNo
17719898Hair Styling and Sunscreen CompoundApril 2022March 2023Allow1110NoNo
17719573HAIR CARE CREAM COMPOSITION AND METHOD OF USEApril 2022September 2023Allow1711NoNo
17713611ORAL CARE COMPOSITIONSApril 2022March 2024Allow2410NoNo
17657769BROAD SPECTRUM SUNBLOCK TRANSFER FILM AND DEVICEApril 2022October 2023Allow1820YesNo
17711500Methods for Treating Metastatic Pancreatic Cancer Using Combination Therapies Comprising Liposomal Irinotecan and OxaliplatinApril 2022April 2025Abandon3710NoNo
17706783Compositions Containing IbrutinibMarch 2022January 2024Allow2100NoNo
17764406TABLETIZATION OF PEPTIDE SELF-ASSEMBLIES AND METHODS OF MAKING AND USING THE SAMEMarch 2022December 2024Allow3300NoNo
17696981Topical Lotion Composition, Methods Of Use, And Methods Of PreparationMarch 2022October 2023Allow1920NoNo
17692362Jehovah-Rapha Miracle Hair OilMarch 2022December 2022Allow910NoNo
17691002COMPOSITIONS AND METHODS OF USE THEREOF FOR ANTISEPTIC MOUTH RINSESMarch 2022June 2023Allow1600NoNo
17689042Hydroxyapatite, Cosmetic, Food, And Method For Producing The SameMarch 2022September 2024Allow3011YesNo
17683415AVOBENZONE-DENDRIMER CONJUGATESMarch 2022March 2024Allow2510NoNo
17674046COMPOSITION FOR APPLICATION TO A SURFACE OF SKIN OF A USERFebruary 2022March 2024Allow2520YesNo
17584212READY TO USE DICLOFENAC STICK PACKSJanuary 2022February 2024Allow2510NoNo
17581477TOPICAL COMPOSITIONS CONTAINING ROFECOXIB AND METHODS OF MAKING AND USING THE SAMEJanuary 2022November 2023Allow2200NoNo
17628503USE IN AN ELECTRIC PERFUME DIFFUSER OF AN AQUEOUS PERFUME COMPOSITION CONTAINING A SURFACTANT AND A PRESERVATIVEJanuary 2022June 2025Allow4120NoNo
17574020COMPOSITIONS FOR FACILITATING TOPICAL ADMINISTRATION OF VITAMIN D WHILE PROTECTING AGAINST UV LIGHTJanuary 2022March 2024Allow2630YesNo
17557477COSMETIC COMPOSITION CAPABLE OF STRENGTHENING EPIDERMAL TIGHT JUNCTIONS FOR THE PREVENTION AND/OR TREATMENT OF ATOPIC DERMATITISDecember 2021January 2023Allow1300NoNo
17553128COMPOSITIONS FOR THERAPY AND HEALTH CONTAINING AMINO ACIDS WITH BITTER TASTEDecember 2021September 2023Allow2110NoNo
17551721INSECT CONTROL PRODUCT FOR CATS AND DOGSDecember 2021April 2023Allow1610NoNo
17544222LIPO-AMINO ACID ALKYL ESTERS AS SPF BOOSTERSDecember 2021June 2023Allow1820NoNo
17535970Compositions Incorporating Avobenzone-Calix[8]-PO3H2 ComplexNovember 2021September 2022Allow1000NoNo
17456274NANOPARTICLES COMPRISING TACROLIMUSNovember 2021October 2023Allow2310NoNo
17534282METHODS AND COMPOSITIONS FOR TREATMENT OF PULMONARY HYPERTENSION AND OTHER LUNG DISORDERSNovember 2021March 2022Allow400YesNo
17530954NO SCENT TOPICAL MOSQUITO CONTROL PRODUCTNovember 2021April 2025Abandon4110NoNo
17526237TEETH CLEANING COMPOSITIONNovember 2021June 2023Allow1910NoNo
17512347NANOEMULSION COSMETIC COMPOSITION AND PROCESS FOR PREPARING SAMEOctober 2021March 2024Allow2930NoNo
17450639AFFECTION GOLD HAIR CARE COMPOSITION AND METHODOctober 2021September 2023Abandon2310NoNo
17489516TOPICAL MONTELUKAST FORMULATIONSSeptember 2021July 2023Allow2210NoNo
17478773ANTIMICROBIAL SKINCARE COMPOSITIONSeptember 2021September 2024Allow3611YesNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner HOLLOMAN, NANNETTE.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
10
Examiner Affirmed
7
(70.0%)
Examiner Reversed
3
(30.0%)
Reversal Percentile
45.2%
Lower than average

What This Means

With a 30.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
52
Allowed After Appeal Filing
20
(38.5%)
Not Allowed After Appeal Filing
32
(61.5%)
Filing Benefit Percentile
60.5%
Higher than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 38.5% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is above the USPTO average, suggesting that filing an appeal can be an effective strategy for prompting reconsideration.

Strategic Recommendations

Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.

Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.

Examiner HOLLOMAN, NANNETTE - Prosecution Strategy Guide

Executive Summary

Examiner HOLLOMAN, NANNETTE works in Art Unit 1612 and has examined 842 patent applications in our dataset. With an allowance rate of 66.0%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 27 months.

Allowance Patterns

Examiner HOLLOMAN, NANNETTE's allowance rate of 66.0% places them in the 19% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by HOLLOMAN, NANNETTE receive 1.68 office actions before reaching final disposition. This places the examiner in the 47% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by HOLLOMAN, NANNETTE is 27 months. This places the examiner in the 55% percentile for prosecution speed. Prosecution timelines are slightly faster than average with this examiner.

Interview Effectiveness

Conducting an examiner interview provides a +15.6% benefit to allowance rate for applications examined by HOLLOMAN, NANNETTE. This interview benefit is in the 59% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 28.4% of applications are subsequently allowed. This success rate is in the 42% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 28.6% of cases where such amendments are filed. This entry rate is in the 33% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 88.9% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 65% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 77.3% of appeals filed. This is in the 65% percentile among all examiners. Of these withdrawals, 55.9% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.

Petition Practice

When applicants file petitions regarding this examiner's actions, 48.7% are granted (fully or in part). This grant rate is in the 58% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 1.2% of allowed cases (in the 70% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).

Quayle Actions: This examiner issues Ex Parte Quayle actions in 2.5% of allowed cases (in the 68% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.